
Danish pharmaceutical firm Leo Pharma has entered a collaboration agreement with Canadian biotech firm Sequence Bio to use the latter’s proprietary discovery platform to identify dermatological targets, Sequence Bio has announced in a press release.
Sequence Bio is a commercial biotech company from Newfoundland. Under the terms of a three-year long deal, the company will be responsible for conducting a number of analyses of samples from cohorts across multiple dermatologic indications.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app